Abstract
The noninvasive assessment of bone turnover has markedly improved in the past few years with the development of sensitive and specific markers of bone formation and bone resorption. Markers of bone formation in serum include total and bone-specific alkaline phosphatase, osteocalcin, and type I collagen carboxyterminal extension peptide. Assessment of bone resorption can be achieved by measuring plasma tartrate-resistant acid phosphate and the urinary excretion (and possibly serum levels) of bone type I collagen degradation products: hydroxyproline, hydroxylysine glycosides, and, more recently, the pyridinium crosslinks (pyridinoline and deoxypyridinoline) and associated peptides. The immunoassay of human osteocalcin and bone alkaline phosphatase for formation and the pyridinoline crosslinks measured by high-pressure liquid chromatography or by immunoassay for bone resorption are currently the most sensitive and specific markers of bone turnover for the clinical assessment of osteoporosis. Using these new markers, several studies have shown that bone turnover increases after the menopause and remains elevated in late postmenopausal and elderly women. An increased bone turnover rate is related to a high rate of bone loss in postmenopausal women and to a decreased bone mass in elderly women. Recent data suggest that some of the new immunoassays for pyridinoline crosslinks could predict the subsequent risk of hip fracture in elderly women. Thus, bone markers might be used in combination with bone mass measurement to improve the prognostic assessment of postmenopausal women, i.e., their risk of developing osteoporosis and ultimately fractures. Treatment of postmenopausal women with antiresorptive drugs such as estrogens, bisphosphonates, and calcitonin induces a rapid decrease in the levels of bone markers that is correlated with the long-term effect of such treatments on bone mass. Thus, bone markers should be very useful in monitoring treatment efficacy in patients with osteoporosis.
Similar content being viewed by others
References
Crilly RG, Jones MM, Horsman A, et al. (1980) Rise in plasma alkaline phosphatase at the menopause. Clin Sei 53: 341–342
Brown JP, Delmas PD, Arlot M, et al. (1987) Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis. J Clin Endocrinol Metab 64:954–959
Podenphant J, Johansen JS, Thomsen K, et al. (1987) Bone turnover in spinal osteoporosis. J Bone Miner Res 2:497–503
Moss DVV (1982) Alkaline phosphatase isoenzymes. Clin Chem 28:2007–2016
Farley JR, Chesnut CJ, Baylink DJ (1981) Improved method for quantitative determination in serum alkaline phosphatase of skeletal origin. Clin Chem 27:2002–2007
Duda RJ, O’Brien JF, Katzmann JA, et al. (1988) Concurrent assays of circulating bone gla-protein and bone alkaline phosphatase: effects of sex. ase, and metabolic bone disease. J Clin Endocrinol Metab 66:951–957
Hill CS, Wolfen RL (1986) The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chem Acta 186:315–320
Garnero P, Delmas PD (1993) Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometrie assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77(4): 1046–1053
Price PA (1987) Vitamin K-dependent bone proteins. In: Conn DV, Martin TJ, Meunier PJ (eds) Calcium regulation and bone metabolism. Basic and clinical aspects, vol 9. Elsevier Science Publishers, New York, pp 419–426
Price PA, Parthemore JG, Deftos JL (1980) New biochemical marker for bone metabolism. J Clin Invest 66:878–883
Price PA, Williamson MK, Lothringer JW (1981) Origin of vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem 256:12760–12766
Lian JB, Gundberg CM ( 1988) Osteocalcin: biochemical considerations and clinical applications. Clin Orthop 226:267–291
Delmas PD, Stenner D, Wanner HW, et al. (1983) Serum bone gla-protein increases with aging in normal women: implications for the mechanism of age-related bone loss. J Clin Invest 71:1316–1321
Thiede MA, Smock SL, Petersen DN, et al. (1994) Presence of messenger of ribonucleic acid encoding osteocalcin, a marker of bone turnover, in bone marrow megakaryocytes and peripheral blood platelets. Endocrinology 135:929–937
Delmas PD, Wilson DM, Mann KGT et al. (1983) Effect of renal function on plasma levels of bone gla-protein. J Clin Endocrinol Metab 57:1028–1030
Delmas PD (1990) Biochemical markers of bone turnover for the clinical assessment of metabolic disease. Endocrinol Metab Clin North Am 19 (1): 1–18
Brown JP, Delmas PD, Malaval L, et al. (1984) Serum bone gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet i: 1091–1093
Charles P, Poser JW, Mosekilde L. et al. (1985) Estimation of bone turnover evaluated by 47 calcium kinetics: efficiency of serum bone gamma-carboxyglutamic acid containing protein, serum alkaline phosphatase and urinary hydroxyproline excretion. J Clin Invest 76:2254–2258
Delmas PD, Malaval L, Arlot ME, et al. (1985) Serum bone gla-protein compared to bone histomorphometry in endocrine diseases. Bone 6:329–341
Delmas PD, Demiaux B, Malaval L, et al. (1986) Serum bone gla-protein (osteocalcin) in primary hyperparathyroidism and in malignant hypercalcemias: comparison with bone histomorphometry. J Clin Invest 77:985–991
Bataille R, Delmas P, Sany J (1987) Serum bone gla-protein in multiple myeloma. Cancer 59:329–334
Gundberg C, Weinstein RS. Multiple immunoreactive forms in uremic serum (1986) J Clin Invest 77:1762–1767
Tracy RP, Andrianorivo A, Riggs BL, et al. (1990) Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: a study of sources of variation in assay results. J Bone Miner Res 5:451–461
Taylor AK, Linkart S, Mohan S, et al. (1990) Multiple osteocalcin fragments in human urine and serum as detected by a midmoiecule osteocalcin radioimmunoassay. J Clin Endocrinol Metab 70:467–472
Garnero P, Grimaux M, Seguin P, et al. (1994) Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 9(2):255–264
Delmas PD, Christiansen C, Mann KG, et al. (1990) Bone gla-protein (osteocalcin) assay standardization report. J Bone Miner Res 1:5–11
Simon LS, Krane SMK (1983) Procollagen extension peptides as markers of collagen synthesis. In: Frame B, Potts JT Jr (eds) Clinical disorders of bone and mineral metabolism. Excerpta Medica, Amsterdam, the Netherlands, pp 108–111
Parfitt AM, Simon LS, Villanueva AR, et al. (1987) Procollagen type I carboxy-terminal extension peptide in scrum as a marker of collagen biosynthesis in bone: correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 2:427–436
Hassager C, Fabbri-Mabelli G, Christiansen C (1993) The effect of the menopause and hormone-replacement therapy on serum carboxyterminal propeptide of type I collagen. Osteoporos Int 3:50–52
Smedsrod B, Melkko J, Ristelli L, et al. (1990) Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 271:345–350
Prockop OJ, Kivirikko KI (1968) Hydroxyproline and the metabolism of collagen. In: Gould BS (ed) Treatise on collagen. Academic Press, New York, pp 215–246
Prockop OJ, Kivirikko KI, Tuderman K, et al. (1979) The biosynthesis of collagen and its disorders. N End J Med 301: 13–23
Krane SM, Kantrowitz FG, Byrne M, et al. (1977) Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. J Clin Invest 59:819–827
Vloro L, Mucelli RSP, Gazzarrini C. et al. (1988) Urinary ß-1-galactosyi-O-hydroxylysine (GH) as a marker of collagen turnover of bone. Calcif Tissue Int 42:87–90
Li CY. Chuda RA, Lam WKW, et al. (1973) Acid phosphatase in human plasma. J Lab Clin Med 82:446–460
Minkin C (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34:285–290
Stepan JJ, Silinkova-Malkova E, Havrenek T, et al. (1983) Relationship of plasma tartrate-resistant acid phosphatase to the bone isoen/yme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta 133:189–200
Stepan JJ, Pospichal J, Presl J, et al. (1987) Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 8:279–284
Piedra C, Torres R, Rapado A, et al. (1989) Serum tartrate-resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis. Calcif Tissue Int 45:58–60
Kraenzlin M, Lau KHW, Liang L (1990) Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J Clin Endocrinol Metab 71:442–451
Cheun CK, Panesar NS, Haines C, et al. (1995) Immunoassay of tartrate-resistant acid phosphatase in serum. Clin Chem 41:679–686
Fujimoto D, Morigachi T, Ishida T, et al. (1978) The structure of pyridinoline, a collagen crosslink. Biochem Biophys Res Commun 84:52–57
Eyre DR (1987) Collagen crosslinking amino-acids. Methods Enzymol 144:115–139
Eyre DR, Koob TJ, Van Ness KP (1984) Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Anal Biochem 137:380–388
Eyre DR, Dickson IR, Van Ness KP (1988) Collagen cross-linking in human bone and articular cartilage: age-related changes in the content of mature hydroxypyridinium residues. Biochem J 252:495–500
Seibel MJ, Robins SP, Bilezikiau JP (1992) Urinary pyridinium crosslinks of collagen. Trends Endocrinoi Metab 3: 263–270
Black D, Duncan A, Robins SP (1988) Quantitative analysis of the pyridinium crosslinks of collagen in urine using ionpaired reversed-phase high-performance liquid chromatography. Anal Biochem 169:197–203
Beardsworth LJ, Eyre DR, Dickson IR (1990) Changes with age in the urinary excretion of lysyl and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J Bone Miner Res 5:671–676
Uebelhart D, Schlemmer A, Johansen J, et al. (1991) Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J Clin Endocrinol Metab 72:367–373
Eastell R, Hampton L, Colwell A (1990b) Urinary collagen crosslinks are highly correlated with radio isotopic measurements of bone resorption. In: Christiansen C, Overgaard K (eds) Proc 3rd Int Symp on Osteoporosis. Osteopress, Aalborg, Denmark, pp 469–470
Delmas PD, Schlemmer A, Gineyts E, et al. (1991) Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 6:639–644
Uebelhart D, Gineyts E, Chapuy MC, et al. (1990) Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner Res 8: 87–96
Colwell A, Eastell R, Assiri AMA, et al. (1990) Effect of diet on deoxypyrinoline excretion, vol 2. In: Christiansen C, Overgaard K (eds) Osteoporosis. Osteopress, Aalborg, Denmark, pp 520–591
Schlemmer A, Hassager C, Jensen SB, et al. (1992) Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 74: 476–480
Eastell R, Calvo MS, Burritt MF, et al. (1992) Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J Clin Endocrinol Metab 74:487–494
Blumsohn A, Herringion K, Harmon RA, et al. (1994) The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab 79:730–735
Seyedin S, Zuk R, Kung V, et al. (1993) An immunoassay to urinary pyridinoline: the new marker of bone resorption. J Bone Miner Res 8:635–642
Robins SP, Woitge H, Hesley R, et al. (1994) Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643–1649
Hanson DA, Weiss MAE, Bollen AM, et al. (1992) A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251–1258
Risteli J, Elomaa I, Niemi S. et al. (1993) Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clm Chem 39:635–640
Bonde H, Quist P, Fidelins C, et al. (1994) Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:2022–2025
Delmas PD, Gineyts E, Bertholin A, et al. (1993) Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget’s disease. J Bone Miner Res 5:643–648
Garnero P, Gineyts E, Riou JP, et al. (1994) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 3:780–785
Hassager C, Risteli J, Risteli L, et al. (1992) Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J Bone Miner Res 7:1307–1311
Hassager C, Jensen LT, Podenphant J, et al. (1994) The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 54:30–33
Garnero P, Gineyts E, Arbault P, et al. (1995) Different effects of bisphosphonate and estrogen therapy on free and peptidebound crosslinks excretion. J Bone Miner Res 10:641–649
Eastell R, Delmas PD, Hodgson SF, et al. (1988) Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics and biochemical markers. J Clin Endocrinol Metab 67:741–748
Garnero P, Sornay-Rendu E, Delmas PD, et al. (1996) Increased bone turnover in late postmenopausal women is a major risk of osteoporosis. J Bone Miner Res 11:337–349
Slemenda C, Hui SL, Longcope C, et al. (1987) Sex steroids and bone mass: a study of changes about the time of menopause. J Clin Invest 80:1261–1269
Johansen JS, Riis BJ, Delmas PD, et al. (1988) Plasma BGP: an indicator of spontaneous bone loss and effect of estrogen treatment in postmenopausal women. Eur J Clin Invest 18: 191–195
Hansen MA, Overgaard K, Riis BJ, et al. (1991) Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 years study. BMJ 303:961–964
Riis BJ, Hansen MA, Jensen K, et al. (1996) Low bone mass and fast rate of bone loss at menopause—equal risk factors for future fracture: a 15-year follow-up study. Bone 19:9–12
Thompson SP, White DA, Hosking DJ. et al. (1980) Changes in osteocalcin alter femoral neck fracture. Ann Clin Biochem 26:487–491
Delmi M, Rapin CH, Bengoa JM, et al. (1990) Dietary supplementation in elderly patients with fractured neck of femur. Lancet 335:1013–1016
Akesson K, Vergnaud P, Gineyts E, et al. (1993) Impairment of bone turnover in elderly women with hip fracture. Calcif Tissue Int 53:162–169
Garnero P, Hausher E, Chapuy MC, et al. (1996) Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res (in press)
Civitelli R, Gonnelli S, Zacchei F, et al. (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:1268–1274
Garnero P, Shih WJ, Gineyts E, et al. (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693–1700
Harris ET, Gertz BJ, Genant HK, et al. (1993) The effect of short-term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76(6): 1399–1403
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garnero, P., Delmas, P.D. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 59 (Suppl 1), S2–S9 (1996). https://doi.org/10.1007/s002239900168
Issue Date:
DOI: https://doi.org/10.1007/s002239900168